

Participant Information Leaflet

ProMOTE—IR800 IAB2M Study (Stage 1)

Prostate Molecular Targeting to Enhance surgery using IR800 IAB2M

We would like to invite you to take part in a study called ProMOTE—IR800 IAB2M. This study aims to test a new way of being able to see prostate cancer cells during surgery. Before you decide whether to take part, it is important that you understand why the research is being done and what it would involve for you. Please take time to read this information, and discuss it with others if you wish. If you have any questions please ask a member of the research team who will be happy to discuss any aspect of the study with you.

What is the purpose of the ProMOTE—IR800 IAB2M study?

This study aims to test whether a ‘marker’ called IR800 IAB2M, which is injected as a drug, makes it easier for surgeons to see prostate cancer cells during surgery.

IR800 IAB2M is attached to a fluorescent dye which shines in the dark (and can bind to and highlight prostate cancer cells. This was shown to work very well in animals, but has not yet been tested in patients. The researchers think that being able to see cancer cells more clearly during surgery will help the surgeon to remove all of the cancer cells, which will help to stop the cancer coming back. It will also help to avoid unnecessarily removing normal cells, which would improve outcomes after the prostate is removed, particularly related to urinary leakage and sexual activity.

The researchers want to test whether IR800 IAB2M can bind to and highlight only prostate cancer cells during surgery, without highlighting any other tissue, which doesn’t have cancer. They also want to find out the best dose (20mg or 50mg) and time to give the drug to patients before surgery. The lower dose will be tested first at 24 hours before surgery, if it highlights the prostate cancer cells well, without highlighting healthy tissue, there will be no need to change the timing or test the higher dose in patients. The dose you are given will depend on whether the drug has already been tested in patients and what the results showed.

The study also aims to look at whether there are any specific changes within the genetic make-up of each cell (the DNA) that can cause them to become cancerous or spread. To answer this question, the researchers will perform genetic tests on the tissue samples taken at the time of diagnosis, and those taken during surgery. The results will help the researchers to understand the differences between normal and cancerous cells. The researchers hope to find out which changes in DNA lead to prostate cancer development and progression.

Why have I been asked to take part in the ProMOTE—IR800 IAB2M study?

You have been asked to consider taking part because you have been diagnosed with prostate cancer and you have chosen to have surgery to remove your prostate. We plan to involve up to 20 patients like yourself in Stage 1 of this study.

Do I have to take part?

No, taking part in a research study is entirely voluntary. We will go through this patient information leaflet with you and answer any questions you might have. You can also talk to anyone else (e.g. family or GP) about your decision whether or not to take part. You do not have to decide straight away. If you decide to take part you are still free to withdraw at any time and without giving a reason. Whether you take part or not will not affect the standard of care you receive.

What will happen to me if I decide to take part?

You will be invited to attend an information appointment to discuss the study with a member of the research team. If you decide to take part in the study you will be asked to sign an informed consent form.

You will be given the IR800 IAB2M drug via an injection. It takes some time for the drug to bind to prostate cancer cells, so you will be given the drug 24 to 48 hours before surgery. The surgery will be conducted as per routine NHS procedure using keyhole surgery and a special camera. The camera is used to identify the dye, as explained to you by your treating consultant. The prostate will be removed and biopsies from any tissues highlighted by the dye will be taken. These biopsies will be looked at by a doctor who studies diseased tissue (histopathologist) to find out whether they contain cancerous cells. If any cancerous cells are found outside of the prostate, we will discuss the results and the best course of action with you at your routine follow up visit.


After surgery you will receive usual NHS care, including follow-up visits and regular Prostate-Specific Antigen (PSA) tests. The research team will access and record your routine PSA result.

Will I have to attend any extra clinic visits?

You will need to come to the hospital for an extra clinic visit either 24 or 48 hours before surgery to have the injection. We will reimburse your travel expenses for this extra visit. You will need to stay for at least 2 hours after the injection to make sure that you feel well. When the staff at the hospital are happy that you are well, you will be able to go home again before you need to come back on the morning of your operation. If you have the injection 24 hours before surgery, you will be able to stay the night before at the hospital if you would like.

All study follow up visits will be at the same time as routine clinical visits, and you will not have to attend any extra follow up visits as part of the study.

The diagram on the next page shows the steps involved in this study.



What are the possible disadvantages and risks in taking part?

This is the first time that the IR800 IAB2M drug is being tested in patients, but a related product (^{89}Zr -Df-IAB2M), which is made of the same active ingredient (IAB2M), has been used in clinical trials. The active ingredient and the dye (IR800) attached to the drug were both shown to be safe when tested separately. Because it takes some time for the drug to work, you will need to come to the hospital for an extra visit, either 24 or 48 hours before your operation, and you will need to stay for two hours following the injection to make sure that you are feeling well afterwards. There is potential for a hypersensitivity or allergic response following the injection, so you will be monitored for two hours to make sure that you don't have an adverse reaction

Apart from receiving an injection before surgery, your treatment and follow up will be the same as standard NHS care. The injection and the use of a cannula (thin tube used to

administer medication) carry a small risk of infection and haematoma (a swelling containing blood).

You will be given a contact card with 24-hour contact details in case you feel unwell or notice any side effects once you leave clinic after having the injection, and you may contact the research team during office hours (details on page 6).

What are the potential benefits of taking part?

Participation in the study will not directly benefit you. The main benefit of you taking part will be the information that we can gather as a result. This may help us improve treatment options for men with high-risk prostate cancer in the future.

What happens if I want to stop taking part in the study?

You are free to decline to join the study and may withdraw at any time in the future. This will not affect any treatment you might receive, now or in the future. If you decide to withdraw, inform the person who gave you this information sheet, or the appropriate researcher as listed at the end of this leaflet. Any data and samples collected before withdrawal will remain part of the study unless you have specific objections.

In addition, the Investigator may discontinue a participant from the study at any time if it is considered necessary for any reason. This will not affect your treatment in any way.

What will happen to the samples I give?

Small tissue samples may be taken during your surgery for research in addition to those taken as part of normal diagnostic processes. This won't affect the routine assessment of your diagnostic pathology samples. These extra samples and your routine pathology samples (which will be stored in a pathology diagnostic archive) may be used in research.

Your tissue samples obtained during surgery will be used for research including genetic tests which will help the researchers to understand the differences between normal and cancerous cells.

Your DNA samples will be assigned a code and your data will be identifiable only by this number. The material given to researchers will not have information that identifies you. However, your DNA is unique to you so it can never be completely anonymous.

With your consent, your samples will be stored anonymously for use in future ethically approved research studies.

They will be used mainly by local researchers, but ethically approved research projects may take place working together with other hospitals, universities, non-profit institutions or commercial laboratories worldwide.

What if something goes wrong?

The University of Oxford, as Sponsor, has appropriate insurance in place in the unlikely event that you suffer any harm as a direct consequence of your participation in this study. NHS indemnity operates in respect of the clinical treatment, which is provided. If you wish to complain about any aspect of the way in which you have been approached or treated during the course of this study, please contact the trial team (promote@nds.ox.ac.uk), The Chief Investigator (Prof Freddie Hamdy, freddie.hamdy@nds.ox.ac.uk), or the University of Oxford Clinical Trials and Research Governance (CTRG) office (tel. 01865 (6)16480 email ctrng@admin.ox.ac.uk).

The Patient Advisory Liaison Service (PALS) is a confidential NHS service that can provide you with support for any complaints or queries you may have regarding the care you receive as an NHS patient. PALS is unable to provide information about this research study. The contact details for the Churchill Hospital PALS Office are Tel: 01865 235855 / Email: PALS@ouh.nhs.uk.

Will my participation in the study be kept confidential?

Yes. All information collected about you during the course of the research, including from your medical records, will be kept strictly confidential. Everyone who takes part in the study will be assigned a code number and all of the data relating to each person will be held on a computer database and will only be linked to that code number, and not to people's names or addresses. All samples relating to the study will only be labelled with the code number.

Responsible members of the University of Oxford, the Oxford University Hospitals NHS Foundation Trust and the regulatory authorities may be given access to data for monitoring and/or audit of the study to ensure that the research is complying with applicable regulations.

With your consent we will access your medical notes to obtain your health status for 6 weeks for follow-up purposes.

Will my GP be informed of my participation in the study?

With your consent, we will notify your GP of your participation in the study.

Who is organising and funding the study?

The study is conducted by the University of Oxford, and funded by Cancer Research UK (CR-UK grant C1380/A18444). The researchers include a team of specialised doctors, scientists, technical staff and nurses. Our team is experienced and has conducted similar research in the field.

What will happen to the results of this study?

Research findings will be used to confirm whether IR800 IAB2M helps the surgeon to see prostate cancer cells and to decide whether a larger study should be carried out.

Any updates about the study will be added to the Surgical Intervention Trials Unit website (www.situ.ox.ac.uk) when they become available.

If a larger study is carried out, the results will be published in academic journals and presented at scientific conferences. It will not be possible to identify you from any report or publication placed in the public domain.

Who has reviewed the study?

All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee, to protect participants' interests. This study has been reviewed and given favourable opinion by South Central – Oxford C Research Ethics Committee.

What if I have any other concerns? Who should I contact?

You will be given as much time as you feel you need to discuss any issues or questions involving this research during your appointment with the researchers and study nurses. If you have any cause to complain about any aspect of the way in which you have been approached or treated during the course of this study, the normal National Health Service complaints mechanisms are available to you and are not compromised in any way because you have taken part in a research study.

If you have any concerns or wish to discuss the study further, please contact one of the following:

Surgical Research Team, Email: srt@nds.ox.ac.uk, Tel: 01865 235944 or 01865 235943

Prof Freddie Hamdy, Chief Investigator, Email: freddie.hamdy@nds.ox.ac.uk, Tel: 01865 617123

Thank you for considering taking part.